{"entity":{"id":"nct06603376","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated","aka":[],"tldr":"A phase 2 trial in colorectal cancer, run by Shanghai Changzheng Hospital, now recruiting.","summary":"Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06603376 by Shanghai Changzheng Hospital, with a registry enrolment figure of 75 participants, started 2024-09-01 and due to reach its primary completion in 2026-08-31. Interventions recorded: FOLFIRI + Vemurafenib + Cetuximab; FOLFIRI ± Bevacizumab. Conditions listed: Colorectal Carcinoma. Primary outcome: Objective response rate. Colorectal eligibility wording from the registry: \"* Patients with advanced colorectal adenocarcinoma confirmed by histology or cytology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06603376","url":"https://clinicaltrials.gov/study/NCT06603376"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06603376","phase":"2","setting":"A Randomized, Multicenter, Controlled Study of Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","sponsor":"Shanghai Changzheng Hospital","participation":[{"nct":"NCT06603376","source":"https://clinicaltrials.gov/study/NCT06603376","fetchedAt":"2026-10-07T16:54:49.791Z","studySha256":"8335b8f64b9d348bd77d519bd679380e55f8e77db7395178d510dd47635977d8","overallStatus":"RECRUITING","lastUpdatePosted":"2024-09-19","leadSponsor":"Shanghai Changzheng Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":75,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-09-01","startedType":"actual","enrolled":75,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06603376/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}